Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, HC Wainwright Says

Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, according to analysts at HC Wainwright & Co. LLC.

Analysts led by Mitchell S. Kapoor on Monday slashed their price target on the stock to $0 — a rare move — from $10, while maintaining a sell recommendation. The cut comes as the drugmaker refused to voluntarily pause shipments of its lead therapy following a request by the US Food and Drug Administration after three deaths were linked to the company’s gene therapies.